Evotec SE’s Seattle-based subsidiary Just – Evotec Biologics, Inc. has entered a collaboration with OncoResponse, Inc., a biotech company developing human antibodies for multiple high value targets associated with immunosuppressive myeloid biology. OncoResponse’s lead product candidate, OR2805, is a fully human antibody that reverses immunosuppression in the tumor microenvironment and promotes greater cancer killing, leading to higher response rates. Just – Evotec Biologic...